Related Experiment Videos
[Multi-targeted antifolate therapy roe non-small cell lung cancer and mesothelioma]
1Institut Gustave Roussy, 94800 Villejuif, France. tle-che@igr.fr
Abstract:
Multi-targeted antifolate (MTA) is an anti-metabolite with useful activity in the treatment of non-operable patients presenting with non-small cell lung cancer. Its good efficacy and tolerability profile as first-line therapy was demonstrated in phase II studies of MTA as monotherapy. The use of MTA as second-line therapy with or without a platinum analog also provides good results. It should be observed that, in combination with cisplatin (C), docetaxel or gemcitabine (G), MTA presents synergistic efficacy: two phase II protocols have shown that the MTA/C combination as first-line therapy presented high efficacy (objective response: 39-45%) and low toxicity. These results are promising and also seem to be observed in an ongoing phase II study evaluating MTA/G. In the treatment of mesothelioma, promising activity was observed for the MTA/C combination, and this activity is under evaluation in ongoing phase II and phase III studies.
Insights
Multi-targeted antifolate (MTA) shows promise for non-small cell lung cancer and mesothelioma. Combinations with chemotherapy agents like cisplatin demonstrate high efficacy and low toxicity in early trials.
Area of Science:
- Oncology
- Pharmacology
Context:
- Non-small cell lung cancer (NSCLC) and mesothelioma are significant global health challenges.
- Chemotherapy remains a cornerstone in the treatment of these malignancies.
Purpose:
- To evaluate the efficacy and tolerability of multi-targeted antifolate (MTA) in various cancer settings.
- To explore the synergistic potential of MTA in combination therapies.
Summary:
- Multi-targeted antifolate (MTA) exhibits favorable efficacy and tolerability as a monotherapy and in combination regimens for non-operable non-small cell lung cancer.
- Combinations of MTA with cisplatin or gemcitabine show synergistic efficacy, with high objective response rates (39-45%) and low toxicity in first-line NSCLC treatment.
- Promising activity of MTA/cisplatin has also been observed in mesothelioma, with ongoing studies to further evaluate its potential.
Impact:
- MTA represents a potentially valuable therapeutic option for patients with non-small cell lung cancer and mesothelioma.
- Combination strategies involving MTA may improve treatment outcomes and patient survival.
- Further clinical evaluation is warranted to establish MTA's role in standard oncological care.